Disposable products developer Merit Medical Systems has signed a $100 million agreement with Becton Dickinson (BD) to purchase assets that BD is divesting in connection with its acquisition of interventional device developer C.R. Bard.
Merit will acquire soft-tissue core-needle biopsy devices including the Achieve programmable automatic biopsy system, the Temno biopsy system, and Tru-Cut biopsy needles. It also plans to purchase the Aspira pleural effusion drainage kits and Aspira peritoneal drainage system currently marketed by Bard, it said.
